IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation

Giuliana Guggino, Francesco Ciccia, Andrea L. Neimann, Alexander A. Aksenov, Carles Ubeda, Julia Manasson, Leopoldo N. Segal, Jose C. Clemente, Michelle H. Badri, Adriana Heguy, Roxana Coras, Matthew Stapylton, David S. Wallach, Parvathy V. Girija, Drew R. Jones, Gary Solomon, Francesco Ciccia, Monica Guma, Richard Bonneau, Pieter C. DorresteinJose U. Scher, Soumya M. Reddy

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome of psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.
Original languageEnglish
Number of pages41
JournalARTHRITIS & RHEUMATOLOGY
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation'. Together they form a unique fingerprint.

Cite this